Donna Hall
Nurse Practitioner · White House, TNNPI 1710984182
Payments from drug & device makers
Across 306 payments — averaging $18.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$943
- AbbVie$910
- AstraZeneca$614
- Lilly USA, LLC$550
- Pfizer$439
- GSK$355
- plus $2K from 29 others
What the payments were for
- Food & beverage$5,47998%
- Education$1002%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 49 | $943 |
| AbbVie | 58 | $910 |
| AstraZeneca | 23 | $614 |
| Lilly USA, LLC | 46 | $550 |
| Pfizer | 27 | $439 |
| GSK | 15 | $355 |
| Astellas Pharma US Inc | 13 | $353 |
| Otsuka America Pharmaceutical, Inc. | 10 | $178 |
| Exact Sciences | 9 | $143 |
| Phathom Pharmaceuticals, Inc. | 6 | $103 |
| Boehringer Ingelheim | 6 | $99 |
| Abbott | 5 | $85 |
| Corcept Therapeutics | 3 | $71 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $68 |
| Novartis | 3 | $61 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $58 |
| Sumitomo Pharma America, Inc. | 3 | $55 |
| Averitas Pharma Inc. | 2 | $52 |
| Bayer | 3 | $48 |
| Johnson & Johnson(2 entities) | 3 | $46 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $38 |
| Axsome Therapeutics, Inc. | 1 | $35 |
| Boston Scientific | 1 | $34 |
| Esperion Therapeutics, Inc. | 2 | $33 |
| Dexcom, Inc. | 1 | $27 |
| Hologic Sales And Service, LLC | 1 | $24 |
| Fidia Pharma USA Inc. | 1 | $21 |
| Lundbeck LLC | 1 | $21 |
| Philips North America LLC | 1 | $21 |
| Seqirus USA Inc | 1 | $19 |
| Radius Health, Inc. | 1 | $17 |
| Antares Pharma, Inc. | 1 | $16 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
| Merck | 1 | $14 |
| Smith+Nephew | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$280
- AIRSUPRA$155
- FARXIGA$155
- TRELEGY ELLIPTA$122
How this compares
$5,579 in reported general payments places this provider in the 90th percentile of 2,662 nurse practitioner providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 49 | $59,588 |
| JardianceEmpagliflozin | 54 | $45,640 |
| MounjaroTirzepatide | 30 | $31,784 |
| TradjentaLinagliptin | 32 | $26,246 |
| JanuviaSitagliptin Phosphate | 28 | $23,335 |
| Tresiba Flextouch U-200Insulin Degludec | 14 | $17,948 |
| XareltoRivaroxaban | 15 | $17,482 |
| FarxigaDapagliflozin Propanediol | 16 | $17,352 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $14,987 |
| EliquisApixaban | 11 | $8,465 |
| Valsartan | 77 | $5,064 |
| Novolog FlexpenInsulin Aspart | 13 | $4,071 |
| Tolterodine Tartrate ErTolterodine Tartrate | 16 | $3,525 |
| Atorvastatin Calcium | 243 | $3,121 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $1,812 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $99 | $71,88686 claims |
| Novo NordiskOzempic | $943 | $59,58849 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $614 | $32,33933 claims |
| Lilly USA, LLCMounjaro | $550 | $31,78430 claims |
| MerckJanuvia | $14 | $23,33528 claims |
| Johnson & JohnsonXarelto | $46 | $17,48215 claims |
| PfizerEliquis | $439 | $8,46511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,662 nurse practitioner providers in Tennessee.
Other nurse practitioner in White House
- Amy HatcherMurfreesboro$1.1M
- Karen RodenKnoxville$265K
- Susan UtleyNashville$194K
- Whitney EricksonMemphis$159K
- Erica HembreeKnoxville$125K
- Brooke FaughtNashville$89K
- Lauren WelchNashville$71K
- Cara StoutKingsport$71K
- S Marie HamiltonOoltewah$64K
- Cynthia WilsonChattanooga$62K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.